Atara licenses T cell therapy to Pierre Fabre for up to $640 million 06-Nov-2023 By Jonathan Smith As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.